Standish M. Fleming

Background

Mr. Standish M. Fleming, also known as Stan, serves as a Managing Member at Forward Ventures, Forward Ventures II, L.P., Forward Ventures IV, L.P. and Forward Ventures V, L.P. Mr. Fleming co-founded the Forward Ventures and Forward Ventures II in 1993 and also served in an advisory position with Forward Ventures from February 1992 to April 1993. Mr. Fleming has helped start more than 15 companies, and served at founding Chief Executive Officer of eight. At Forward, he ... has invested in almost every segment of the health-care industry, including pharmaceuticals, biologics, diagnostics, devices, services, and software. Mr. Fleming has managed both platform and product companies and investments in the portfolio and led or participated in financings at all levels from pre-start-up to PIPES in public companies, in both debt and equity. He has helped raise and manage six venture funds totaling more than $500 million and has served on the Boards of 19 venture-backed companies. Mr. Fleming is a 22 year veteran of early-stage venture capital and biotech investing. He served as the President, and Chief Executive Officer of GeneSys Therapeutics. He served at Vermillion, Inc. and Corixa Corporation. Mr. Fleming served as the initial President and Chief Executive Officer of Triangle Pharmaceuticals, Actigen, GenQuest, Deltagen, and CombiChem. He was the President of the Biotechnology Venture Investors Group. He served as Principal at Ventana Capital Management, LLC. He serves as a Director of Ambit and Nereus Pharmaceuticals, Inc. He has been a Director of CONNECT since July 1995. He served as a Director of Ambit Biosciences Corporation from June 2001 to November 10, 2014. He was a Director of Gryphon Therapeutics, Inc., MIGENIX Corp, Arizeke Pharmaceuticals Inc., Tandem Medical, Inc., and Kémia, Inc. He served as a Director of Sanarus Medical Inc (aka Sanarus Technologies, LLC). He served as Director of Triangle Pharmaceuticals, Inc. since July 1995. Mr. Fleming was a founding Board Member of Ciphergen Biosystems, Triangle Pharmaceuticals, and Gryphon Sciences. He served on the boards of Converge Medical, Doctors on Line, EndiCOR, First Dental Health, IntensiCare, and MitoKor. He served as Director of Acorda Therapeutics, Inc. from 2004 to September 19, 2006. Mr. Fleming was also the Chairman at GeneSys Therapeutics. He earned an M.B.A. from the UCLA Graduate School of Management and a B.A. from Amherst College.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.